PC
GILD icon

Permanens Capital’s Gilead Sciences GILD Stock Holding History

Permanens Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46
Closed -$3K – 60
2021
Q2 		$3K Hold
46
– – ﹤0.01% 99
2021
Q1 		$3K Hold
46
– – ﹤0.01% 116
2020
Q4 		$3K Hold
46
– – ﹤0.01% 114
2020
Q3 		$3K Hold
46
– – ﹤0.01% 102
2020
Q2 		$4K Hold
46
– – ﹤0.01% 96
2020
Q1 		$3K Hold
46
– – ﹤0.01% 96
2019
Q4 		$3K Hold
46
– – ﹤0.01% 119
2019
Q3 		$3K Hold
46
– – ﹤0.01% 86
2019
Q2 		$3K Hold
46
– – ﹤0.01% 88
2019
Q1 		$3K Buy
+46
New +$3.06K ﹤0.01% 84

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Permanens Capital's GILD Position: Q3 2021 in Review

Permanens Capital sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 46 shares — an estimated $3K sold.

Permanens Capital first reported a position in GILD in Q1 2019 and held it in 10 quarters. The position peaked at $4K in Q2 2020. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Permanens Capital reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
  • Permanens Capital sold 46 Gilead Sciences shares in Q3 2021, an estimated $3K.
  • Permanens Capital first reported a position in Gilead Sciences in Q1 2019 and held it in 10 quarters.
  • Permanens Capital's Gilead Sciences position peaked at $4K in Q2 2020.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Permanens Capital's 13F filing for Q3 2021, filed 12 Nov 2021.